CN109851562A - A kind of Telmisartan crystal and preparation method thereof - Google Patents

A kind of Telmisartan crystal and preparation method thereof Download PDF

Info

Publication number
CN109851562A
CN109851562A CN201910091311.6A CN201910091311A CN109851562A CN 109851562 A CN109851562 A CN 109851562A CN 201910091311 A CN201910091311 A CN 201910091311A CN 109851562 A CN109851562 A CN 109851562A
Authority
CN
China
Prior art keywords
telmisartan
crystal
telmisartan crystal
water
ray powder
Prior art date
Application number
CN201910091311.6A
Other languages
Chinese (zh)
Inventor
楼永军
左丽丽
Original Assignee
浙江省食品药品检验研究院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 浙江省食品药品检验研究院 filed Critical 浙江省食品药品检验研究院
Priority to CN201910091311.6A priority Critical patent/CN109851562A/en
Publication of CN109851562A publication Critical patent/CN109851562A/en

Links

Abstract

The invention discloses a kind of Telmisartan crystal and preparation method thereof, the X-ray powder diffraction collection of the Telmisartan crystal is 5.0 ± 0.2,6.1 ± 0.2,7.3 ± 0.2,9.2 ± 0.2,11.3 ± 0.2,12.3 ± 0.2,11.9 ± 0.2,13.4 ± 0.2,14.8 ± 0.2,15.8 ± 0.2,16.8 ± 0.2,17.6 ± 0.2,18.5 ± 0.2,19.1 ± 0.2,20.0 ± 0.2,20.5 ± 0.2,21.3 ± 0.2,21.9 ± 0.2,22.8 ± 0.2,23.5 ± 0.2,24.2 ± 0.2,24.8 ± 0.2,25.7 ± 0.2,25.9 ± 0 in 2 θ of the angle of diffraction .2, 27.1 ± 0.2, 27.8 ± 0.2, 28.8 ± 0.2, 29.4 ± 0.2, 30.1 ± 0.2, 30.6 ± 0.2, 31.0 ± 0.2, 32.0 ± 0.2, 32.7 ± 0.2, 33.4 ± 0.2, 34.2 ± 0.2, 350 ± 0.2, 35.7 ± 0.2, 36.4 ± 0.2, 37.1 ± 0.2, 38.7 ± 0.2, 39.5 ± 0.2, 40.8 ± 0.2, 41.5 ± 0.2, 42.2 ± 0.2, 42.6 ± 0.2, 43.4 ± 0.2, 46.0 ± 0.2, 46.9 ± 0.2, 49.8 ± 0.2, 50.5 ± 0.2, 52.6 ± 0.2, have at 54.6 ± 0.2 and spreads out Penetrate peak.Telmisartan crystal of the present invention has the advantages that purity is high and preferably stability, solubility and crystallinity, and preparation method is realized by anti-solvent method, and this method is simple, is suitable for industrialized production.

Description

A kind of Telmisartan crystal and preparation method thereof

Technical field

The present invention relates to drug crystallization technical fields, and in particular to a kind of Telmisartan crystal and preparation method thereof.

Background technique

Since in physicochemical property, (such as solubility, stability, mobility, resists dissolution rate between same drug different crystal forms Compressibility etc.) on have differences, and the physicochemical property of crystal form drug is related to the bioavilability of drug and clinical efficacy, therefore The polymorphic of research solid drugs just becomes one of important research content very important in drug development process.

Telmisartan, chemical name 4 '-[(Isosorbide-5-Nitrae '-dimethyl -2 '-propyl [2,6 '-two -1H- benzimidazole] -1 ' - Base) methyl]-[1,1 '-dibiphenylyl] -2- carboxylic acid is a kind of non-peptides angiotensin-ii receptor retarding agent, the property of can choose , irreversible inhibition angiotensin-ii receptor, for treating hypertension, structural formula are as follows:

Telmisartan crystal disclosed in existing commercially available and patent (such as US2006/0276525), in stability, dissolution There is also certain defects in the performance indicators such as degree, crystallinity and production technology.Therefore, it is badly in need of searching out a kind of with better The performance indicators such as stability, solubility, crystallinity, the Telmisartan crystal being convenient for industrialized production, to improve Telmisartan Drug quality and clinical efficacy.

Summary of the invention

The technical problem to be solved by the present invention is to overcome the technological deficiency of background technique, a kind of Telmisartan crystal is provided And preparation method thereof.Telmisartan crystal of the present invention has the advantages that purity is high and preferably stability, solubility and crystallinity, Preparation method is realized by anti-solvent method, and this method is simple, is suitable for industrialized production.

It is as follows that the present invention solves technical solution used by above-mentioned technical problem:

A kind of Telmisartan crystal, the X-ray powder diffraction collection of the Telmisartan crystal are 5.0 in 2 θ of the angle of diffraction ±0.2、6.1±0.2、7.3±0.2、9.2±0.2、11.3±0.2、12.3±0.2、11.9±0.2、13.4±0.2、14.8 ±0.2、15.8±0.2、16.8±0.2、17.6±0.2、18.5±0.2、19.1±0.2、20.0±0.2、20.5±0.2、 21.3±0.2、21.9±0.2、22.8±0.2、23.5±0.2、24.2±0.2、24.8±0.2、25.7±0.2、25.9± 0.2、27.1±0.2、27.8±0.2、28.8±0.2、29.4±0.2、30.1±0.2、30.6±0.2、31.0±0.2、 32.0±0.2、32.7±0.2、33.4±0.2、34.2±0.2、350±0.2、35.7±0.2、36.4±0.2、37.1± 0.2、38.7±0.2、39.5±0.2、40.8±0.2、41.5±0.2、42.2±0.2、42.6±0.2、43.4±0.2、 There is diffraction maximum at 46.0 ± 0.2,46.9 ± 0.2,49.8 ± 0.2,50.5 ± 0.2,52.6 ± 0.2,54.6 ± 0.2.

Preferably, the Telmisartan crystal has following X-ray powder diffraction collection:

It is highly preferred that the Telmisartan crystal has X-ray powder diffraction collection substantially as shown in.

Preferably, the infrared spectroscopy of the Telmisartan crystal is in 3215 ± 2cm-1、3052±2cm-1、2968±2cm-1、 2934±2cm-1、2874±2cm-1、2742±2cm-1、2451±2cm-1、1954±2cm-1、1700±2cm-1、1614± 2cm-1、1595±2cm-1、1536±2cm-1、1508±2cm-1、1479±2cm-1、1458±2cm-1、1444±2cm-1、1414 ±2cm-1、1394±2cm-1、1338±2cm-1、1322±2cm-1、1307±2cm-1、1286±2cm-1、1260±2cm-1、 1237±2cm-1、1128±2cm-1、1093±2cm-1、1045±2cm-1、1005±2cm-1、926±2cm-1、878±2cm-1、 867±2cm-1、850±2cm-1、824±2cm-1、795±2cm-1、766±2cm-1、748±2cm-1、738±2cm-1、706± 2cm-1、662±2cm-1、649±2cm-1、630±2cm-1、598±2cm-1、575±2cm-1、541±2cm-1There is absorption peak at place.

Preferably, the Raman spectrum of the Telmisartan crystal is in 1609 ± 2cm-1、1521±2cm-1、1444±2cm-1、 1271±2cm-1、1111±2cm-1There is absorption peak at place.

A kind of preparation method of Telmisartan crystal includes the following steps: that it is 25 that Telmisartan crude product is dissolved in volume ratio ~50: 50: 50 formic acid-water-isopropanol in the mixed solvent;It is heated to reflux;Water-first that volume ratio is 100: 1~10 is added dropwise The anti-solvent of alcohol;Stand crystallization;Recycle Telmisartan crystal.

Compared with prior art, the beneficial effects of the present invention are:

Telmisartan crystal of the present invention has the advantages that purity is high and preferably stability, solubility and crystallinity, system Preparation Method is realized by anti-solvent method, and this method is simple, is suitable for industrialized production.

Detailed description of the invention

Fig. 1 is the X-ray powder diffraction figure of Telmisartan crystal made from the embodiment of the present invention 1;

Fig. 2 is the high-efficient liquid phase chromatogram of Telmisartan crystal made from the embodiment of the present invention 1;

Fig. 3 is the infrared spectrogram of Telmisartan crystal made from the embodiment of the present invention 1;

Fig. 4 is the Raman spectrogram of Telmisartan crystal made from the embodiment of the present invention 1.

Specific embodiment

In order to better understand the content of the present invention, it is described further combined with specific embodiments below with attached drawing.Ying Li Solution, these embodiments are only used for that the present invention is further described, rather than limit the scope of the invention.In addition, it should also be understood that, After having read content of the present invention, person skilled in art makes some nonessential changes or adjustment to the present invention, Still fall within protection scope of the present invention.

Telmisartan crude product described in Examples 1 to 5 can be amorphous substance or known any crystal form, such as commercial product or It is made using the preparation method as described in patent US2006/0276525.

Embodiment 1

Take 5.0g Telmisartan crude product set in a round bottom flask, be added about 130ml formic acid-water-isopropanol (50: 50: 50) mixed solvent is heated to reflux to whole dissolutions, continues the 2h that flows back, and cooling room temperature is added dropwise about 50ml water-methanol (100: 1) Anti-solvent, stand, filter, obtained solid drying at room temperature, weighing, obtain 2.4g.

Embodiment 2

Take 5.0g Telmisartan crude product set in a round bottom flask, be added about 130ml formic acid-water-isopropanol (50: 50: 50) mixed solvent is heated to reflux to whole dissolutions, continues the 2h that flows back, and cooling room temperature is added dropwise about 50ml water-methanol (100: 5) Anti-solvent, stand, filter, obtained solid drying at room temperature, weighing, obtain 2.1g.

Embodiment 3

Take 5.0g Telmisartan crude product set in a round bottom flask, be added about 130ml formic acid-water-isopropanol (50: 50: 50) mixed solvent is heated to reflux to whole dissolutions, continues the 2h that flows back, cooling room temperature, be added dropwise about 50ml water-methanol (100: 10) anti-solvent is stood, and is filtered, obtained solid drying at room temperature, and weighing obtains 2.2g.

Embodiment 4

Take 5.0g Telmisartan crude product set in a round bottom flask, be added about 130ml formic acid-water-isopropanol (35: 50: 50) mixed solvent is heated to reflux to whole dissolutions, continues the 2h that flows back, and cooling room temperature is added dropwise about 50ml water-methanol (100: 5) Anti-solvent, stand, filter, obtained solid drying at room temperature, weighing, obtain 3.1g.

Embodiment 5

Take 5.0g Telmisartan crude product set in a round bottom flask, be added about 130ml formic acid-water-isopropanol (25: 50: 50) mixed solvent is heated to reflux to whole dissolutions, continues the 2h that flows back, and cooling room temperature is added dropwise about 50ml water-methanol (100: 5) Anti-solvent, stand, filter, obtained solid drying at room temperature, weighing, obtain 2.9g.

As a result:

1 crystal form is investigated

Telmisartan crystal prototype, is measured using Powder X-ray Diffractometer made from Example 1, diffraction data It is shown in Table 1, map is shown in Fig. 1.

Instrument: D8-advance Powder X-ray Diffractometer

X-ray target: Cu

Power supply: 40kv/40mA

The angle of diffraction (2 θ) scanning range: 3 °~80 °

Step-length: 0.02 °

Telmisartan crystal X-ray powder diffraction data made from 1 embodiment 1 of table

As seen from Figure 1, find that the X-ray powder diffraction figure of Telmisartan crystal prototype made from embodiment 1 is aobvious after measured It is shown with and is different from having diffraction maximum reported in the literature, show that this product is new crystal.

Meanwhile the peak type of this product diffraction maximum is sharp, shows that crystallinity is good.

2 purity detectings

Telmisartan crystal prototype made from Example 1, is measured using HPLC method, chromatographic condition and preparation method As follows, map is shown in Fig. 2.

Instrument: Agilent1260 high performance liquid chromatograph

Chromatographic condition:

Mobile phase: (25:75 contains 0.2% triethylamine, extremely with phosphorus acid for adjusting pH to 0.1% potassium dihydrogen phosphate-methanol 5.0)

Wavelength: 230nm

Chromatographic column: Venusil MP C18(5 μm, 4.6 × 250mm)

Test sample is prepared: being weighed Telmisartan crystal prototype 10mg made from embodiment 1, is placed in 20ml volumetric flask, uses Methanol dissolves and is diluted to scale, and precision measures 2ml, sets in 20ml volumetric flask, with methanol dilution to scale to get.

It uses area normalization method to measure Telmisartan crystal prototype purity made from embodiment 1 as 98.7%, shows this Product purity is good.

3 solubility tests

Telmisartan crystal prototype made from Example 1 is appropriate, finely ground, is placed in the n-octyl alcohol of 25 DEG C of certain volumes, Every strength shaking in 5 minutes 30 seconds, continue 30 minutes, supersaturated solution is made, centrifugation measures its concentration using HPLC, i.e., ?.The solubility test of different Telmisartan crystal the results are shown in Table 2.

The solubility test result of the different Telmisartan crystal of table 2

The results show that this product solubility is more preferable, higher than the product of commercialized product and existing patent report.

4 other characteristic spectrums

4.1 infrared spectrum measurement

Telmisartan crystal prototype made from Example 1, is measured, map is shown in Fig. 3 using KBr tabletting.

Instrument: 6700Thermo Fisher Nicole infrared spectrophotometer

Infrared spectrum measurement the results show that this product in 3215 ± 2cm-1、3052±2cm-1、2968±2cm-1、2934± 2cm-1、2874±2cm-1、2742±2cm-1、2451±2cm-1、1954±2cm-1、1700±2cm-1、1614±2cm-1、1595 ±2cm-1、1536±2cm-1、1508±2cm-1、1479±2cm-1、1458±2cm-1、1444±2cm-1、1414±2cm-1、 1394±2cm-1、1338±2cm-1、1322±2cm-1、1307±2cm-1、1286±2cm-1、1260±2cm-1、1237± 2cm-1、1128±2cm-1、1093±2cm-1、1045±2cm-1、1005±2cm-1、926±2cm-1、878±2cm-1、867± 2cm-1、850±2cm-1、824±2cm-1、795±2cm-1、766±2cm-1、748±2cm-1、738±2cm-1、706±2cm-1、662±2cm-1、649±2cm-1、630±2cm-1、598±2cm-1、575±2cm-1、541±2cm-1There is absorption peak at place.

4.2 Raman spectroscopy

Instrument: Invia Rama laser co-focusing micro-Raman spectroscopy

Telmisartan crystal prototype made from Example 1 is measured Raman map using 532nm laser light source, figure Spectrum is shown in Fig. 4.

Raman spectroscopy the results show that this product in 1609 ± 2cm-1、1521±2cm-1、1444±2cm-1、1271± 2cm-1、1111±2cm-1There is absorption peak at place.

5 stability of crystal form are investigated

Telmisartan crystal prototype made from the embodiment 1 for being placed at room temperature for 3 months is taken, according to the method for " investigation of 1 crystal form " It is measured, the powder x-ray diffraction map and powder X-ray when rigid preparation for placing 3 months samples as the result is shown spread out The diffraction maximum position consistency in map is penetrated, shows that the crystal form of this product does not change, this product stability of crystal form is good.

Above description is not limitation of the present invention, and the present invention is also not limited to the example above.The art it is common Within the essential scope of the present invention, the variations, modifications, additions or substitutions made also should belong to protection of the invention to technical staff Range.

Claims (6)

1. a kind of Telmisartan crystal, which is characterized in that the X-ray powder diffraction collection of the Telmisartan crystal is in diffraction 2 θ of angle is 5.0 ± 0.2,6.1 ± 0.2,7.3 ± 0.2,9.2 ± 0.2,11.3 ± 0.2,12.3 ± 0.2,11.9 ± 0.2,13.4 ±0.2、14.8±0.2、15.8±0.2、16.8±0.2、17.6±0.2、18.5±0.2、19.1±0.2、20.0±0.2、 20.5±0.2、21.3±0.2、21.9±0.2、22.8±0.2、23.5±0.2、24.2±0.2、24.8±0.2、25.7± 0.2、25.9±0.2、27.1±0.2、27.8±0.2、28.8±0.2、29.4±0.2、30.1±0.2、30.6±0.2、 31.0±0.2、32.0±0.2、32.7±0.2、33.4±0.2、34.2±0.2、350±0.2、35.7±0.2、36.4± 0.2、37.1±0.2、38.7±0.2、39.5±0.2、40.8±0.2、41.5±0.2、42.2±0.2、42.6±0.2、 There is diffraction at 43.4 ± 0.2,46.0 ± 0.2,46.9 ± 0.2,49.8 ± 0.2,50.5 ± 0.2,52.6 ± 0.2,54.6 ± 0.2 Peak.
2. a kind of Telmisartan crystal as described in claim 1, which is characterized in that the Telmisartan crystal has following X-ray powder diffraction collection:
3. a kind of Telmisartan crystal as claimed in claim 2, which is characterized in that the Telmisartan crystal has substantially X-ray powder diffraction collection as shown in Figure 1.
4. a kind of Telmisartan crystal as described in claim 1, which is characterized in that the infrared spectroscopy of the Telmisartan crystal In 3215 ± 2cm-1、3052±2cm-1、2968±2cm-1、2934±2cm-1、2874±2cm-1、2742±2cm-1、2451± 2cm-1、1954±2cm-1、1700±2cm-1、1614±2cm-1、1595±2cm-1、1536±2cm-1、1508±2cm-1、1479 ±2cm-1、1458±2cm-1、1444±2cm-1、1414±2cm-1、1394±2cm-1、1338±2cm-1、1322±2cm-1、 1307±2cm-1、1286±2cm-1、1260±2cm-1、1237±2cm-1、1128±2cm-1、1093±2cm-1、1045± 2cm-1、1005±2cm-1、926±2cm-1、878±2cm-1、867±2cm-1、850±2cm-1、824±2cm-1、795±2cm-1、766±2cm-1、748±2cm-1、738±2cm-1、706±2cm-1、662±2cm-1、649±2cm-1、630±2cm-1、 598±2cm-1、575±2cm-1、541±2cm-1There is absorption peak at place.
5. a kind of Telmisartan crystal as described in claim 1, which is characterized in that the Raman spectrum of the Telmisartan crystal In 1609 ± 2cm-1、1521±2cm-1、1444±2cm-1、1271±2cm-1、1111±2cm-1There is absorption peak at place.
6. the preparation method of Telmisartan crystal as claimed in any one of claims 1 to 5, wherein, which is characterized in that including as follows Step: Telmisartan crude product is dissolved in formic acid-water-isopropanol in the mixed solvent that volume ratio is 25~50: 50: 50;Heating Reflux;The anti-solvent for the water-methanol that volume ratio is 100: 1~10 is added dropwise;Stand crystallization;Recycle Telmisartan crystal.
CN201910091311.6A 2019-01-30 2019-01-30 A kind of Telmisartan crystal and preparation method thereof CN109851562A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910091311.6A CN109851562A (en) 2019-01-30 2019-01-30 A kind of Telmisartan crystal and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910091311.6A CN109851562A (en) 2019-01-30 2019-01-30 A kind of Telmisartan crystal and preparation method thereof

Publications (1)

Publication Number Publication Date
CN109851562A true CN109851562A (en) 2019-06-07

Family

ID=66896894

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910091311.6A CN109851562A (en) 2019-01-30 2019-01-30 A kind of Telmisartan crystal and preparation method thereof

Country Status (1)

Country Link
CN (1) CN109851562A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1336920A (en) * 1999-01-19 2002-02-20 贝林格尔英格海姆法玛公司 Telmisartan polymorphs, methods for producing same and their use in prepn. of a medicament
US20060276525A1 (en) * 2005-05-18 2006-12-07 Itai Adin Processes of preparing highly pure telmisartan form A, suitable for pharmaceutical compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1336920A (en) * 1999-01-19 2002-02-20 贝林格尔英格海姆法玛公司 Telmisartan polymorphs, methods for producing same and their use in prepn. of a medicament
US20060276525A1 (en) * 2005-05-18 2006-12-07 Itai Adin Processes of preparing highly pure telmisartan form A, suitable for pharmaceutical compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ROBERT E. DINNEBIER等: "Structural Characterization of Three Crystalline Modifications of Telmisartan by Single Crystal and High-Resolution X-ray Powder Diffraction", 《JOURNAL OF PHARMACEUTICAL SCIENCES》 *
陈佳星: "《河南工业大学专业硕士学位论文》", 1 May 2015 *

Similar Documents

Publication Publication Date Title
Dengale et al. Preparation and characterization of co-amorphous Ritonavir–Indomethacin systems by solvent evaporation technique: Improved dissolution behavior and physical stability without evidence of intermolecular interactions
Paudel et al. Raman spectroscopy in pharmaceutical product design
CN101838261B (en) Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US8217021B2 (en) Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof
US20070060645A1 (en) Purification of cinacalcet
Shayanfar et al. Drug–drug coamorphous systems: characterization and physicochemical properties of coamorphous atorvastatin with carvedilol and glibenclamide
Basavoju et al. Indomethacin–saccharin cocrystal: design, synthesis and preliminary pharmaceutical characterization
Mealey et al. Influence of solvent on crystal nucleation of risperidone
US4894459A (en) Process for the preparation of morphologically homogeneous forms of thiazole derivatives
Zhou et al. Determination of osthole in rat plasma by high-performance liquid chromatograph using cloud-point extraction
KR20170134737A (en) Preparation of dicyclopratin
CN105510459B (en) A kind of detection method of febuxostat raw material
Offerdahl et al. Quantitation of crystalline and amorphous forms of anhydrous neotame using 13C CPMAS NMR spectroscopy
EP2782912A1 (en) Solid state forms of vilazodone and vilazodone hydrochloride
CN107505305B (en) Method for rapidly analyzing illegal addition of sildenafil analogue in yang-strengthening health-care product
CN104655751B (en) A kind of detect the method for organic solvent residual in dapoxetine
Qu et al. A fluorescence “switch-on” approach to detect hydrazine in aqueous solution at neutral pH
CN105223223B (en) The quantitative detecting method of active ingredient in Buddhist nun's bulk drug is replaced in the life of two p-methyl benzenesulfonic acid edge
CN104749288B (en) A kind of liquid phase chromatography analytical method of Parecoxib Sodium about material
Radhakrishna et al. LC method for the determination of assay and purity of sibutramine hydrochloride and its enantiomers by chiral chromatography
CN105237536A (en) Substituted heterocycle fused gamma-carbolines solid
Lin et al. Preparation, characterization, and evaluation of dipfluzine–benzoic acid co-crystals with improved physicochemical properties
Li et al. Solid-liquid equilibrium and thermodynamic properties of dipyridamole form II in pure solvents and mixture of (N-methyl pyrrolidone+ isopropanol)
Braga et al. Molecular salts of anesthetic lidocaine with dicarboxylic acids: solid-state properties and a combined structural and spectroscopic study
CN104744445A (en) Crystal form of tyrosine kinase inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination